Matteo Giovanni Della Porta

• 1999 he obtained his Medical Degree with honours at the University of Pavia Medical School, Pavia, Italy
• 2000–2003 he completed his training in Hematology at the Department of Hematology, University of Ferrara Medical School, Ferrara, Italy, and obtained his Degree with honours
• 2004–2006 he was awarded a postdoctoral fellowship at the Department of Hematology, University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy [Research project: “Genomic and functional characterization of hematopoietic stem cells in myelodysplastic syndromes”.]
• 2008 he hold the position of Associate Professor of Clinical Oncology at the University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy
• 2016 he hold the position of Associate Professor of Hematology at Humanitas University, and Head of Leukemia Unit – Cancer Center, Humanitas Research Hospital

Current research interests mainly concern acute leukemia, myelodysplastic syndromes and myeloproliferative neoplasms (myeloid malignancies)

These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45, Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013;31(28):3557-64: J Clin Oncol. 2016;34(30):3627-3637], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10 and Blood. 2008;112(3):895-902; Leukemia. 2017;31(11):2449-2457] and the CPSS [Blood. 2013;121(15):3005-15] as a valuable tools for risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders, respectively.

• In 2008 he joined the European LeukemiaNet working package on myelodysplastic syndromes, aimed at developing European evidence and consensus-based guidelines for the diagnosis and treatment of myelodysplastic syndromes [Blood. 2013 Oct 24;122(17):2943-64]
• In 2010, he joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011; 365(15):1384-95, Blood. 2011;118(24):6239-46, Blood. 2015 Jul 9;126(2):233-41, Leukemia. 2015 Jan;29(1):66-75].